Stocks-EXEL-Exelixis Inc

EXEL Exelixis Inc

18.57 0.24 (1.31%)
Delayed Prices By NASDAQ, in USD Market Closed
Invest

Performance

8.72% Past Week
Created with Highcharts 4.2.7 /Highstock 4.2.7
Market Cap
6.02B
Day’s Range
18.26
-
18.76
52W Range
14.85
-
23.37
Volume (3M)
3.07M
Price-Earnings Ratio
33.07
Revenue
1.61B

Exelixis Inc Latest News

View All
Top Discussions
MarketUpdates
Edited
$EXEL (Exelixis Inc) Q1 2023 earnings report is expected to be released
9
MAY
REPORTS
Exelixis Inc Q1 2023 earnings report is expected to be released after market open
Notify me
EXEL
EXEL
Exelixis Inc
18.57
0.24
(1.31%)
Trade
MarketUpdates
Edited
$EXEL (Exelixis Inc) Q1 2023 earnings report is expected to be released
MarketUpdates
$EXEL (Exelixis Inc) Q1 2023 earnings report is expected to be released
Henrik Bilevits
𝗣𝗘𝗥𝗙𝗢𝗥𝗠𝗔𝗡𝗖𝗘 𝗝𝗔𝗡𝗨𝗔𝗥𝗬 𝟮𝟬𝟮𝟯 The month of January was a relief compared to 2022, let's hope it continues in February. 𝗠𝘆 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 January: +9.24% 𝗠𝘆 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗰𝗼𝗺𝗽𝗮𝗿𝗲𝗱 𝘁𝗼: ✅ SPX500 January: +6.18% ❌ NSDQ100 January: +10,62% ✅ Warren Buffet January:... Show More
Like CommentShare
null
.
Benjamin Nowak
𝘿𝙚𝙥𝙤𝙩𝙪𝙥𝙙𝙖𝙩𝙚 – 18.01.2023 Ich habe ein paar Korrekturen an meinem Depot vorgenommen. Die Anpassungen sahen wie folgt aus: ᴠᴇʀᴋᴀᴜғ ◼️ $BLDR (Builders FirstSource Inc): Ich habe meine komplette Position mit einem Plus von knapp 17,5% zu einem Kurs von $72,60 geschlossen. Dadurch, dass sich... Show More Translate
Like CommentShare
null
.

About Exelixis Inc

Exelixis Inc is an American biotechnology company based in Alameda, California. Operating internationally, the firm is predominantly an oncology-focused, genomics-based research and drug discovery company involved in the discovery, development, and commercialisation of new therapies aimed at patients suffering from cancers that are traditionally difficult to treat. The firm was founded in 1994. The company is the producer of Cometriq, a treatment approved by the US Food and Drug Administration for the treatment of progressive, metastatic medullary thyroid cancer, and Cabometyx, a treatment for patients with advanced renal cell carcinoma. Other commercial products include Cotellic, a kinase inhibitor used in the treatment of patients with unresectable or metastatic melanoma. The firm has several other products in the pipeline at various stages, with a strong focus on small molecule drug discovery and biotherapeutic treatments primarily aimed at cancer patients. Exelixis Inc has acquired various related companies, including Genomica, Agritope, and X-Ceptor. The firm also collaborates with a number of partners in the industry, such as Invenra, who Exelixis Inc is working with on the development of cancer antibodies, antibody-drug conjugates, and other biologic candidates. The firm trades on the NASDAQ, where it is listed under the stock ticker EXEL. Track price movements by adding EXEL stock to your eToro watchlist.
1.2K
Employees
Alameda, California, US
HQ
1994
Founded
Michael M. Morrissey, PhD
CEO
Show More

Upcoming Earnings

9
MAY
REPORTS
Exelixis Inc Q1 2023 earnings report is expected to be released after market open

Analyst Forecast

Consensus
Moderate Buy
Price Target
24.17

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
59
High
Industry 
Avg. 49 
44
Environment
52
Social
67
Governance

People Also Bought